# A Multi-Omic Platform for Polycystic Ovary Syndrome Characterization and Management

> **NIH NIH R43** · ONEGEVITY HEALTH LLC · 2020 · $155,473

## Abstract

Project Summary/Abstract
Polycystic ovarian syndrome (PCOS) is the most common endocrine disorder in women of
reproductive age. Due to the complex nature of PCOS, diagnosis is often delayed and options for
treatment and self-management are limited. With recent developments in high-throughput, next-
generation and metabolomics technologies, there is now a unique opportunity to utilize a cost-
effective, multi-omic approach to study individuals with PCOS.
In this application, we propose to apply these technologies to examine women with PCOS,
developing a platform that is cost-effective, scalable, integrative, and highly accurate. Our multi-
omic platform (FemBio) will integrate patient’s medical records, genomics, microbiome
(shotgun metagenomics), and metabolomics to create a molecular profile of women with and
without PCOS. This approach has the potential to provide a more comprehensive
characterization of PCOS, to lead to the identification of improved diagnostic markers, and to
allow for the discovery of novel targets for treatment. Moreover, we propose a prospective
observational cohort study including whole genome sequencing, shotgun metagenomic
sequencing of the gut microbiome, fecal metabolomics, serum and urine hormone levels, and
clinical indices in a sample of individuals with PCOS and a healthy control group.
This platform (FemBio) will enable broader accessibility to the latest in molecular assays, multi-
omic quantification, and computational modeling for the general public, which currently is
lacking. In turn, this will improve options for PCOS characterization, long-term management,
and open potentially new treatment options for the millions of women suffering from this
disorder, as well as serve as a large, annotated multi-omic data set that can help the PCOS field
more broadly.

## Key facts

- **NIH application ID:** 10080951
- **Project number:** 1R43HD103568-01
- **Recipient organization:** ONEGEVITY HEALTH LLC
- **Principal Investigator:** Christopher Edward Mason
- **Activity code:** R43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $155,473
- **Award type:** 1
- **Project period:** 2020-09-22 → 2022-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10080951

## Citation

> US National Institutes of Health, RePORTER application 10080951, A Multi-Omic Platform for Polycystic Ovary Syndrome Characterization and Management (1R43HD103568-01). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10080951. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*